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background: Galectin-3 (Gal-3), a beta-galactoside-binding lectin, is a mediator of cardiac fibrosis. Higher circulating Gal-3 concentrations are 
associated with incident heart failure (HF) and cardiovascular (CV) mortality in middle age community cohorts. We sought to determine if Gal-3 
remains robust for CV prognosis in older adults who have comorbidities that could reduce the specificity of the biomarker for cardiac fibrosis.
Methods: Using the Cardiovascular Health Study, a cohort of community dwelling adult’s ≥ 65 years, Gal-3 was measured in 3877 participants 
without HF. Follow-up was for a median of 13.6 years (interquartile range 8.2, 18.2) for incident HF and CV mortality. Gal-3 was analyzed across 
quintiles, as a continuous variable (log transformed) and at its approved cut-off of 17.8 ng/mL.
results: There were 1179 HF and 1025 CV death events in the study population who had a mean age 73 ± 6, 41% male, 83% Caucasian. Those 
with higher Gal-3 concentrations were older, more likely to be male, to be on antihypertensive medications, and have an increased BMI. Risk factors 
such as coronary artery disease, and diabetes did not correlate with greater Gal-3 concentrations. Progressively higher Gal-3 levels were predictive of 
incident HF, but not CV mortality after adjustment for clinical risk factors (see table).
conclusions: Galectin-3 is often increased in older adults. It is an independent predictor of incident HF events, and to a lesser extent of CV 
mortality. 
Event Rate
(/100 person years)
Hazard Ratios (95% CI)
Incident HF 
Unadjusted
(N=3877)
Risk-factor Adjusted (N=3723)
Gal-3 quintile (ng/mL)
Q1 (< 12.105) 2.5 (2.2, 2.8) Reference Reference
Q2 (12.106 -14.45) 2.3 (2.0, 2.7) 0.95 (0.79, 1.15) 0.98 (0.80, 1.18)
Q3 (12.454 - 16.721) 2.4 (2.1, 2.8) 0.99 (0.82, 1.19) 1.01 (0.84, 1.22)
Q4 (16.722 - 20.12) 2.8 (2.5, 3.2) 1.15 (0.96, 1.38) 1.05 (0.86, 1.26)
Q5 (> 20.123) 3.7 (3.3, 4.2) 1.57 (1.32. 1.87) 1.34 (1.11, 1.62)
test for trend p<.001 p=0.004
ln(Gal-3) 1.70 (1.43, 2.02) 1.38 (1.14, 1.67)
Gal-3>17.8 ng/mL (N=1254) 1.43 (1.27, 1.61) 1.23 (1.08, 1.40)
CV Mortality 
Q1 (< 12.105) 1.9 (1.7, 2.2) Reference Reference
Q2 (12.106 -14.45) 1.9 (1.7, 2.2) 1.01 (0.83, 1.24) 1.04 (0.85, 1.27)
Q3 (12.454 - 16.721) 1.9 (1.7, 2.2) 1.01 (0.83, 1.23) 1.05 (0.86, 1.29)
Q4 (16.722 - 20.12) 2.2 (1.9, 2.5) 1.20 (0.99, 1.45) 1.06 (0.87, 1.30)
Q5 (> 20.123) 2.7 (2.4, 3.0) 1.50 (1.24, 1.82) 1.22 (0.99, 1.51)
test for trend p<.001 p=0.09
ln(Gal-3)) 1.59 (1.32, 1.92) 1.26 (1.02, 1.54)
Gal-3>17.8 ng/mL 1.40 (1.24, 1.59) 1.16 (1.01, 1.33)
Risk factor-Adjusted: age, gender, race, systolic BP, diastolic BP, anti- hypertensive medications, coronary heart disease, and diabetes.
